FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912593557> ?p ?o ?g. }

• W2912593557 endingPage "3228" @default.
• W2912593557 startingPage "3220" @default.
• W2912593557 abstract "Abstract Purpose: IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells (Treg). Navoximod is an investigational small-molecule inhibitor of IDO1. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of navoximod in combination with atezolizumab, a PD-L1 inhibitor, in patients with advanced cancer. Patients and Methods: The study consisted of a 3+3 dose-escalation stage (n = 66) and a tumor-specific expansion stage (n = 92). Navoximod was given orally every 12 hours continuously for 21 consecutive days of each cycle with the exception of cycle 1, where navoximod administration started on day −1 to characterize pharmacokinetics. Atezolizumab was administered by intravenous infusion 1,200 mg every 3 weeks on day 1 of each cycle. Results: Patients (n = 157) received navoximod at 6 dose levels (50–1,000 mg) in combination with atezolizumab. The maximum administered dose was 1,000 mg twice daily; the MTD was not reached. Navoximod demonstrated a linear pharmacokinetic profile, and plasma Kyn generally decreased with increasing doses of navoximod. The most common treatment-related AEs were fatigue (22%), rash (22%), and chromaturia (20%). Activity was observed at all dose levels in various tumor types (melanoma, pancreatic, prostate, ovarian, head and neck squamous cell carcinoma, cervical, neural sheath, non–small cell lung cancer, triple-negative breast cancer, renal cell carcinoma, urothelial bladder cancer): 6 (9%) dose-escalation patients achieved partial response, and 10 (11%) expansion patients achieved partial response or complete response. Conclusions: The combination of navoximod and atezolizumab demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer. Although activity was observed, there was no clear evidence of benefit from adding navoximod to atezolizumab." @default.
• W2912593557 created "2019-02-21" @default.
• W2912593557 creator A5007052233 @default.
• W2912593557 creator A5012487596 @default.
• W2912593557 creator A5017217059 @default.
• W2912593557 creator A5020637647 @default.
• W2912593557 creator A5024509581 @default.
• W2912593557 creator A5025563724 @default.
• W2912593557 creator A5026149881 @default.
• W2912593557 creator A5028592995 @default.
• W2912593557 creator A5029805571 @default.
• W2912593557 creator A5035267514 @default.
• W2912593557 creator A5045269140 @default.
• W2912593557 creator A5046419114 @default.
• W2912593557 creator A5047573588 @default.
• W2912593557 creator A5049348377 @default.
• W2912593557 creator A5050335579 @default.
• W2912593557 creator A5050684671 @default.
• W2912593557 creator A5064953304 @default.
• W2912593557 creator A5065206480 @default.
• W2912593557 creator A5069690249 @default.
• W2912593557 creator A5072308451 @default.
• W2912593557 creator A5072492355 @default.
• W2912593557 creator A5084967339 @default.
• W2912593557 creator A5087836238 @default.
• W2912593557 creator A5089962252 @default.
• W2912593557 creator A5090789911 @default.
• W2912593557 creator A5091426116 @default.
• W2912593557 creator A5091727687 @default.
• W2912593557 date "2019-06-01" @default.
• W2912593557 modified "2023-10-14" @default.
• W2912593557 title "Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors" @default.
• W2912593557 cites W1973251492 @default.
• W2912593557 cites W2065958240 @default.
• W2912593557 cites W2075626960 @default.
• W2912593557 cites W2124427232 @default.
• W2912593557 cites W2244492686 @default.
• W2912593557 cites W2273004055 @default.
• W2912593557 cites W2567564314 @default.
• W2912593557 cites W2595109242 @default.
• W2912593557 cites W2602892158 @default.
• W2912593557 cites W2741228199 @default.
• W2912593557 cites W2757648351 @default.
• W2912593557 cites W2758413282 @default.
• W2912593557 cites W2777225646 @default.
• W2912593557 cites W2806431043 @default.
• W2912593557 cites W2807361763 @default.
• W2912593557 cites W2807434325 @default.
• W2912593557 cites W2809526912 @default.
• W2912593557 cites W2888064777 @default.
• W2912593557 doi "https://doi.org/10.1158/1078-0432.ccr-18-2740" @default.
• W2912593557 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7980952" @default.
• W2912593557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30770348" @default.
• W2912593557 hasPublicationYear "2019" @default.
• W2912593557 type Work @default.
• W2912593557 sameAs 2912593557 @default.
• W2912593557 citedByCount "159" @default.
• W2912593557 countsByYear W29125935572019 @default.
• W2912593557 countsByYear W29125935572020 @default.
• W2912593557 countsByYear W29125935572021 @default.
• W2912593557 countsByYear W29125935572022 @default.
• W2912593557 countsByYear W29125935572023 @default.
• W2912593557 crossrefType "journal-article" @default.
• W2912593557 hasAuthorship W2912593557A5007052233 @default.
• W2912593557 hasAuthorship W2912593557A5012487596 @default.
• W2912593557 hasAuthorship W2912593557A5017217059 @default.
• W2912593557 hasAuthorship W2912593557A5020637647 @default.
• W2912593557 hasAuthorship W2912593557A5024509581 @default.
• W2912593557 hasAuthorship W2912593557A5025563724 @default.
• W2912593557 hasAuthorship W2912593557A5026149881 @default.
• W2912593557 hasAuthorship W2912593557A5028592995 @default.
• W2912593557 hasAuthorship W2912593557A5029805571 @default.
• W2912593557 hasAuthorship W2912593557A5035267514 @default.
• W2912593557 hasAuthorship W2912593557A5045269140 @default.
• W2912593557 hasAuthorship W2912593557A5046419114 @default.
• W2912593557 hasAuthorship W2912593557A5047573588 @default.
• W2912593557 hasAuthorship W2912593557A5049348377 @default.
• W2912593557 hasAuthorship W2912593557A5050335579 @default.
• W2912593557 hasAuthorship W2912593557A5050684671 @default.
• W2912593557 hasAuthorship W2912593557A5064953304 @default.
• W2912593557 hasAuthorship W2912593557A5065206480 @default.
• W2912593557 hasAuthorship W2912593557A5069690249 @default.
• W2912593557 hasAuthorship W2912593557A5072308451 @default.
• W2912593557 hasAuthorship W2912593557A5072492355 @default.
• W2912593557 hasAuthorship W2912593557A5084967339 @default.
• W2912593557 hasAuthorship W2912593557A5087836238 @default.
• W2912593557 hasAuthorship W2912593557A5089962252 @default.
• W2912593557 hasAuthorship W2912593557A5090789911 @default.
• W2912593557 hasAuthorship W2912593557A5091426116 @default.
• W2912593557 hasAuthorship W2912593557A5091727687 @default.
• W2912593557 hasBestOaLocation W29125935571 @default.
• W2912593557 hasConcept C111113717 @default.
• W2912593557 hasConcept C112705442 @default.
• W2912593557 hasConcept C121608353 @default.
• W2912593557 hasConcept C126322002 @default.
• W2912593557 hasConcept C143998085 @default.
• W2912593557 hasConcept C197934379 @default.
• W2912593557 hasConcept C2775949291 @default.

• next